![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supplementary Material)
7MB |
| Item Type: | Article |
|---|---|
| Title: | Investigation of the association of serum GFAP and NfL with brain and upper cervical MRI volumes in AQP4-IgG-positive NMOSD and MOGAD |
| Creators Name: | Schindler, Patrick, Grittner, Ulrike, Rust, Rebekka, Asseyer, Susanna, Bellmann-Strobl, Judith, Schmitz-Hübsch, Tanja, Scheel, Michael, Jarius, Sven, Wildemann, Brigitte, Reindl, Markus, Benkert, Pascal, Kuhle, Jens, Paul, Friedemann, Ruprecht, Klemens and Chien, Claudia |
| Abstract: | BACKGROUND: Serum glial fibrillary acidic protein (sGFAP) is associated with disease activity in aquaporin-4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSD). Serum neurofilament light chain (sNfL) is a biomarker for neuroaxonal damage. However, the association of sGFAP and sNfL with magnetic resonance imaging (MRI) volumes in AQP4-IgG+NMOSD is unclear. OBJECTIVES: To investigate the associations of sGFAP and sNfL with brain MRI volumes in AQP4-IgG+NMOSD. DESIGN: Monocentric, retrospective, observational study. METHODS: In 33 clinically stable patients with AQP4-IgG+NMOSD, 17 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and 15 healthy controls (HC), sGFAP and sNfL were measured at 2 (HC = 1) and 3-Tesla MRIs were obtained at 4 (HC = 1) yearly visits. Associations between biomarkers and MRI metrics were evaluated using linear models. RESULTS: In AQP4-IgG+NMOSD, but not in MOGAD and HC, higher sGFAP was associated with lower hippocampus (β = −2.0 (95% confidence interval: −3.4, −0.7), p = 0.004) and thalamus volumes (β = −2.5 (−4.3, −0.7), p = 0.006) and higher MRI cerebrospinal fluid volume (β = 1.8 (0.7, 3.2), p = 0.01), and, statistically less robust, with lower whole brain (β = −2.3 (−5.3, 0.8), p = 0.15) and gray matter volumes (β = −1.8 (−4.0, 0.4), p = 0.10). Furthermore, higher sGFAP (β = −0.06 (−0.11, −0.002), p = 0.04), but not sNfL (β = −0.02 (−0.08, 0.03), p = 0.38), was associated with percent brain volume change in AQP4-IgG+NMOSD. CONCLUSION: The specific associations of sGFAP with brain MRI volumes corroborate sGFAP as a biomarker for disease activity in AQP4-IgG+NMOSD. |
| Keywords: | Biomarker, Glial Fibrillary Acidic Protein (GFAP), Magnetic Resonance Imaging (MRI), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Neurofilament Light Chain (NfL), Neuromyelitis Optica Spectrum Disorders (NMOSD) |
| Source: | Therapeutic Advances in Neurological Disorders |
| ISSN: | 1756-2856 |
| Publisher: | Sage Publications |
| Volume: | 18 |
| Page Range: | 17562864251345792 |
| Date: | 2025 |
| Official Publication: | https://doi.org/10.1177/17562864251345792 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
